Molecular correlates of response to TAR-200 in BCG-unresponsive NMIBC
Автор: VJOncology
Загружено: 2025-11-12
Просмотров: 18
Описание:
Felix Guerrero-Ramos, MD, PhD, Hospital Universitario 12 de Octubre in Madrid, Spain, discusses the Phase IIb SunRISe-1 trial (NCT04640623) of TAR-200 monotherapy in patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ. Analyses assessed baseline tumor genomic alterations, PD-L1 expression, tumor mutational burden, microsatellite instability, and urine tumor DNA minimal residual disease. Clinical responses to TAR-200 were observed across all molecular subtypes, with high rates of complete response and durable outcomes. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
